<DOC>
	<DOCNO>NCT02601963</DOCNO>
	<brief_summary>The purpose study see study drug , FMX-103 , safe give help people moderate-to-severe papulopustular rosacea . The investigational product FMX-103 minocycline foam . Two concentration investigational product , 1.5 % 3 % , study along vehicle . The foam apply daily face 12-week treatment duration study . Approximately 210 patient participate study .</brief_summary>
	<brief_title>Safety Efficacy Study Topical Minocycline Foam Patients With Papulopustular Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Participants age 18 year old . 2 . Participants moderatetosevere rosacea exclude lesion involve eye scalp . 3 . Subject must diagnose rosacea least 6 month prior screen . 1 . History hypersensitivity allergy minocycline , tetracycline component formulation Soybean oil Coconut oil . 2 . Women child bear potential pregnant , lactate ( last 3 month ) plan become pregnant study period . 3 . Moderate severe rhinophyma , dense telangiectasis ( score 3 , severe ) , plaque like facial edema . 4 . Rosacea conglobata fulminans , corticosteroidinduced rosacea isolated pustulosis chin , facial erythrosis know origin rosacea ( e.g. , know carcinoid syndrome ) . 5 . Ocular rosacea ( e.g. , conjunctivitis , blepharitis , keratitis ) sufficient severity require topical ophthalmic systemic antibiotic , papulopustular rosacea require medically indicated systemic treatment . 6 . Bacterial folliculitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>